After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients ...

CAR-T therapy is a highly specialized treatment that requires careful patient selection and close monitoring. Some patients ...

U.S. pharmaceutical company Moderna announced on the 26th (local time) that it will begin developing an “in vivo CAR-T” ...

A new human-in-the-loop AI framework has identified promising CAR T therapy targets in weeks instead of years, with early lab ...

CAR T-cell therapy genetically alters a patient's immune cells to fight certain cancers like lymphoma and leukemia.

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

LONDON — Cellular therapy continues to advance treatment options for severe, refractory autoimmune diseases, according to newly released data presented at the European Alliance of Associations for ...

Target selection leverages DLL3’s high tumor-surface expression in SCLC/LCNEC and limited normal-tissue expression, while dnTGFBR2 “armoring” aims to blunt TGF-β–mediated T-cell suppression. Dose ...

The world's first CAR-T cell therapy targeting solid tumors, developed by a Shanghai-based biopharmaceutical company, has ...

Researchers say approach could be useful for both initial treatment of bladder cancer as well as treatment refractory subsets of tumors.

Dual-target CAR T-cell therapy for recurrent glioblastoma (GBM), delivered directly into the cerebrospinal fluid (CSF), triggers a broad immune response, with natural killer (NK) cell activation ...

Landau, MD, discussed promising results of CAR T-cell therapy in light chain amyloidosis and the challenge of developing ...